BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for More Than 175 Additional Drugs

Overview

Journal AAPS J

Specialty Pharmacology

Date 2015 Nov 22

PMID 26589308

Citations 32

Authors

Chelsea M Hosey

Rosa Chan

Leslie Z Benet

Affiliations

Soon will be listed here.

Abstract

The biopharmaceutics drug disposition classification system was developed in 2005 by Wu and Benet as a tool to predict metabolizing enzyme and drug transporter effects on drug disposition. The system was modified from the biopharmaceutics classification system and classifies drugs according to their extent of metabolism and their water solubility. By 2010, Benet et al. had classified over 900 drugs. In this paper, we incorporate more than 175 drugs into the system and amend the classification of 13 drugs. We discuss current and additional applications of BDDCS, which include predicting drug-drug and endogenous substrate interactions, pharmacogenomic effects, food effects, elimination routes, central nervous system exposure, toxicity, and environmental impacts of drugs. When predictions and classes are not aligned, the system detects an error and is able to self-correct, generally indicating a problem with initial class assignment and/or measurements determining such assignments.

Citing Articles

Determination of Intrinsic Clearance and Fraction Unbound in Human Liver Microsomes and In Vitro-In Vivo Extrapolation of Human Hepatic Clearance for Marketed Central Nervous System Drugs.

Palacharla V, Nirogi R, Kumar N, Nandakumar K Eur J Drug Metab Pharmacokinet. 2024; 50(2):119-135.

PMID: 39724218 DOI: 10.1007/s13318-024-00931-2.

Prediction of the First-Pass Metabolism of a Drug After Oral Intake Based on Structural Parameters and Physicochemical Properties.

Hosseini M, Alizadeh A, Shayanfar A Eur J Drug Metab Pharmacokinet. 2024; 49(4):449-465.

PMID: 38733548 DOI: 10.1007/s13318-024-00892-6.

Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS).

Ashrafi A, Teimouri K, Aghazadeh F, Shayanfar A Eur J Drug Metab Pharmacokinet. 2023; 49(1):1-6.

PMID: 37864650 DOI: 10.1007/s13318-023-00861-5.

DruMAP: A Novel Drug Metabolism and Pharmacokinetics Analysis Platform.

Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y J Med Chem. 2023; 66(14):9697-9709.

PMID: 37449459 PMC: 10388294. DOI: 10.1021/acs.jmedchem.3c00481.

Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential.

Benet L J Pharm Sci. 2023; 112(9):2326-2331.

PMID: 37429358 PMC: 11033615. DOI: 10.1016/j.xphs.2023.07.006.

References

Varma M, Feng B, Obach R, Troutman M, Chupka J, Miller H . Physicochemical determinants of human renal clearance. J Med Chem. 2009; 52(15):4844-52. DOI: 10.1021/jm900403j. View

Yang X, Gandhi Y, Duignan D, Morris M . Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J. 2009; 11(3):511-25. PMC: 2758117. DOI: 10.1208/s12248-009-9124-1. View

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

Skolnik S, Lin X, Wang J, Chen X, He T, Zhang B . Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci. 2010; 99(7):3246-65. DOI: 10.1002/jps.22080. View

Tapaninen T, Backman J, Kurkinen K, Neuvonen P, Niemi M . Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol. 2010; 51(3):359-67. DOI: 10.1177/0091270010365885. View

Chen M, Amidon G, Benet L, Lennernas H, Yu L . The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011; 28(7):1774-8. DOI: 10.1007/s11095-011-0438-1. View

Bateman D . Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet. 1983; 8(6):523-9. DOI: 10.2165/00003088-198308060-00003. View

Gladziwa U, Klotz U . Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet. 1993; 24(4):319-32. DOI: 10.2165/00003088-199324040-00005. View

Sanguinetti M, Jiang C, Curran M, Keating M . A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995; 81(2):299-307. DOI: 10.1016/0092-8674(95)90340-2. View

10.

Trudeau M, Warmke J, Ganetzky B, Robertson G . HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995; 269(5220):92-5. DOI: 10.1126/science.7604285. View

11.

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

12.

Wu C, Benet L . Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005; 22(1):11-23. DOI: 10.1007/s11095-004-9004-4. View

13.

Custodio J, Wu C, Benet L . Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008; 60(6):717-33. PMC: 2292816. DOI: 10.1016/j.addr.2007.08.043. View

14.

Chuasuwan B, Binjesoh V, Polli J, Zhang H, Amidon G, Junginger H . Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J Pharm Sci. 2008; 98(4):1206-19. DOI: 10.1002/jps.21525. View

15.

Shugarts S, Benet L . The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009; 26(9):2039-54. PMC: 2719753. DOI: 10.1007/s11095-009-9924-0. View

16.

Benet L, Broccatelli F, Oprea T . BDDCS applied to over 900 drugs. AAPS J. 2011; 13(4):519-47. PMC: 3231854. DOI: 10.1208/s12248-011-9290-9. View

17.

Broccatelli F, Cruciani G, Benet L, Oprea T . BDDCS class prediction for new molecular entities. Mol Pharm. 2012; 9(3):570-80. PMC: 3295927. DOI: 10.1021/mp2004302. View

18.

Broccatelli F, Larregieu C, Cruciani G, Oprea T, Benet L . Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012; 64(1):95-109. PMC: 3496430. DOI: 10.1016/j.addr.2011.12.008. View

19.

Varma M, Gardner I, Steyn S, Nkansah P, Rotter C, Whitney-Pickett C . pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Mol Pharm. 2012; 9(5):1199-212. DOI: 10.1021/mp2004912. View

20.

Budha N, Frymoyer A, Smelick G, Jin J, Yago M, Dresser M . Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?. Clin Pharmacol Ther. 2012; 92(2):203-13. DOI: 10.1038/clpt.2012.73. View